SynthesisFrontiers in endocrinology2026
Association of sarcopenia and muscle attenuation with clinical outcomes in patients with diabetic foot: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic foot (DF) represents a severe and disabling complication of diabetes, closely linked to ulceration, amputation, functional impairment, and an elevated risk of death. Sarcopenia is a syndrome marked by progressive declines in muscle mass and function. Emerging evidence suggests a possible link between DF and sarcopenia. Nonetheless, a systematic evaluation of the influence of sarcopenia on adverse clinical outcomes in individuals with DF remains unavailable. The present investigation aims to systematically assess and quantitatively synthesize the association of sarcopenia and muscle attenuation with clinical outcomes in those with DF. Methods: A systematic search of Embase, Cochrane, PubMed, Web of Science, SinoMed, China National Knowledge Infrastructure, Wanfang, and VIP databases was conducted from their inception through December 2025. Observational studies enrolling DF individuals aged ≥ 18 years and comparing clinical prognoses between those with and without sarcopenia and muscle attenuation were included. The primary outcomes comprised rates of mortality and amputation. Secondary outcomes encompassed ulcer severity. The NHLBI was adopted for risk-of-bias evaluation. Given substantial between-study heterogeneity, a narrative synthesis was prioritized, with meta-analyses implemented for outcomes amenable to quantitative pooling. Results: Eighteen studies (9 cross-sectional, 4 prospective cohort, 4 retrospective cohort, and 1 retrospective case-control studies) comprising 2,888 individuals were included, of which 9 contributed to the meta-analysis. The meta-analysis revealed that, relative to those without sarcopenia and muscle attenuation, DF individuals with comorbid sarcopenia exhibited an elevated risk of all-cause mortality (HR = 2.38, 95% CI: 1.63-3.48), an association with amputation (OR = 2.11, 95% CI: 1.32-3.38), and a higher proportion of severe ulcers (Wagner grade 4-5) (RR = 1.69, 95% CI: 1.31-2.17). Conclusions: Impaired muscle health was associated with a higher risk of all-cause mortality, higher odds of amputation, and a greater prevalence of severe ulcers in patients with DF. Because the available evidence is observational and heterogeneous, these findings should be considered hypothesis-generating and should not yet be used to support prognostic screening or clinical risk-stratification decisions. Future prospective cohort investigations are necessary to further clarify the temporal relationship and underlying mechanisms. Funding and registration: This study was supported by the Ningxia Natural Science Foundation (Grant Number: 2025AAC030725). This systematic review complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD420251247873). Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251247873.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.